

October 25, 2011

ORIGIO a/s  
A world leader in Assisted Reproductive Technologies (ART)


### Live birth rates support significant effect from EmbryoGen® in patients with previous miscarriage

ORIGIO a/s, a medtech company listed on the Oslo Stock Exchange (OSE: ORO), has today reported results supporting a significant improvement in the live birth rate after In Vitro Fertilization (IVF) treatment when using ORIGIO's novel fertility culture medium, EmbryoGen®. The results will form an essential part of the submission to the USA health authorities, FDA.

EmbryoGen® contains a natural cytokine growth factor (GM-CSF) expressed throughout the woman's reproductive tract. The cytokine is involved in regulation of embryo development and a range of other physiological functions. The purpose of adding GM-CSF to an IVF medium is to optimize the composition of the medium to make it more closely mimic the natural surroundings of the embryo and thereby increase the chance of an ongoing pregnancy after assisted reproduction.

ORIGIO completed in 2010 the world's largest clinical study of IVF culture media, and announced in December 2010 that exposure to EmbryoGen® showed a statistical significant improvement of 44% of the ongoing implantation rate in week 7 for women who have previously experienced miscarriage, either naturally or in relation to an IVF cycle.

A follow-up on children born in the completed study documented that exposure to EmbryoGen® increased the live birth rate for this subgroup by 28% compared to the control group in the difficult patient group of patients with previous miscarriages. The significant increase of 28% in the live birth rate was seen both in terms of per embryo transferred and in terms of per transfer cycle.



Average number of embryos transferred: EmbryoGen®: 1.55; Control 1.56

Number of transfer cycles: EmbryoGen®: 142; Control 147

Twinning rate similar in the 2 groups

Susanne Hauschildt Bendz, Ph.D., CSO, EVP Innovation and Corporate Marketing, comments:

*"We are highly satisfied with these significant results as they clearly support that EmbryoGen® increases the pregnancy outcome for women who have suffered miscarriage. It is a pleasure to offer a new effective solution for this group and thereby help them make their #1 dream come true, with a more gentle treatment."*

ORIGIO has world-wide exclusive rights for human use of IVF media containing GM-CSF. EmbryoGen® received regulatory clearance in the EU (CE-mark) in August 2011 and the product is currently being marketed sequentially in Europe, Asia, Middle East, Africa, Latin America, and Canada.

The total number of fresh ART cycles world-wide is estimated to approximately 1.1 million per year. In general, at least 20% of all pregnancies end in miscarriage, and the primary target group for EmbryoGen<sup>®</sup> is thus believed to be more than 200,000 cycles per year.

#### **Financial guidance**

The new data from the GM-CSF study will not impact ORIGIO's previously announced financial guidance for 2011 and revenue is not expected to materialize significantly until 2012, when the product gradually has been implemented in daily practices.

*For further information, please contact:*

*Jesper Funding Andersen, CEO: +45 4073 0963 or email, [jfandersen@origio.com](mailto:jfandersen@origio.com)*

*Jakob Brix Christensen, Director Investor Relations: +45 2144 4811 or email, [jbrix@origio.com](mailto:jbrix@origio.com)*

#### **About GM-CSF and the clinical study**

*Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) is a cytokine naturally found in the female reproductive organs during early pregnancy. GM-CSF works by binding to receptors on cell surfaces, including oocytes (eggs) and embryos, where it helps to regulate cell division and viability.*

*The GM-CSF study is a multi centre, randomized, parallel group, double-blinded, placebo-controlled, efficacy trial conducted at 11 Danish and 3 Swedish centres. A total of 1,332 patients were enrolled in the study of which 1,319 patients were included, and 1,151 received an embryo transfer.*

*ORIGIO has previously undertaken a safety study on human oocytes from 73 women. The study was conducted at two clinics in Denmark. Its purpose was to investigate whether there was any negative impact on the chromosomes, and the conclusion was that GM-CSF does not increase the risk of abnormalities.*

*ORIGIO has licensed world-wide exclusive rights from the University of Adelaide, Australia, for the human use of ART media containing GM-CSF.*

#### **About ORIGIO a/s**

*ORIGIO a/s is a world leader in Assisted Reproductive Technology (ART) solutions. Through research and innovation, ORIGIO aims to provide the best products to medical professionals to help the #1 dream of every infertile couple come true. ORIGIO currently comprises the three product families, MediCult Media, Humagen Pipets and MidAtlantic Devices, that cater for the broadest range of ART requirements. The medtech company ORIGIO, which is headquartered in Måløv, Denmark, and has subsidiaries in 10 countries, is listed on the Oslo Stock Exchange under the symbol, ORO. For further information, please visit [www.origio.com](http://www.origio.com).*

#### **Forward-Looking Statements**

*Certain statements in this announcement contain forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. There can be no assurance that any of the forward-looking statements identified in this announcement will occur. Conducting studies for investigational products are subject to risks and uncertainties. There can be no assurance that planned studies can be initiated, that planned or ongoing studies can be successfully concluded or concluded in accordance with ORIGIO's anticipated schedule. These factors, and other factors including, but not limited to, those described in ORIGIO's most recent annual report, could cause future results to differ materially from the expectations expressed in this announcement. The forward-looking statements contained in this announcement may become outdated over time. ORIGIO does not assume any responsibility for updating any forward-looking statements.*